Epkinly Market Outlook Through 2030: Understanding The Growth Opportunity
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Epkinly Market Value Growth And Long-Term Outlook
The expansion observed in the past can be linked to an increasing prevalence of Non-Hodgkin lymphoma, the limitations of traditional chemotherapy, breakthroughs in monoclonal antibody research, a rise in approvals for targeted cancer medications, and unresolved requirements within the field of relapsed cancer therapy.
The anticipated growth during the forecast period is due to the increasing adoption of immuno-oncology therapies, the expansion of clinical indications for bispecific antibodies, improved data on patient outcomes, rising oncology healthcare spending, and the growth of specialty cancer centers. Key trends for the forecast period encompass bispecific antibody immunotherapies, an expansion in t-cell engaging oncology drugs, a concentrated focus on relapsed and refractory lymphomas, the administration of oncology drugs subcutaneously, and personalized treatments for hematologic cancers.
Get A Free Sample Report With In-Depth Market Insights:
Epkinly Market Development Factors: What’s Supporting Demand?
The future expansion of the epkinly market is expected to be driven by the increasing need for targeted therapies. These precise treatments aim to block specific molecules responsible for disease progression, particularly in cancers, offering fewer adverse effects compared to conventional methods. The adoption of targeted therapies is growing due to their capacity to provide more effective, personalized treatment options with reduced side effects. Epkinly (epcoritamab) is utilized as a targeted therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, working by binding to CD3 on T cells and CD20 on B cells, thereby directing the immune system to destroy cancerous B cells. For example, data from October 2024, attributed to the National Health Service, a UK-based government department, revealed that 14.5% of HRT (hormone replacement therapy) items in 2023/24 were linked to an HRT prescription prepayment certificate (PPC). This proportion subsequently rose to 21% by June 2024, significantly higher than the 9.7% recorded in June 2023. Thus, the escalating demand for targeted therapies is a primary impetus behind the growth of the epkinly market.
Epkinly Market Segment Analysis And Revenue Potential
The epkinly market covered in this report is segmented –
1) By Indication: Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), Indolent Lymphoma
2) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies
Epkinly Market Transformation Trends: What Innovations Are Driving Change?
A significant trend observed in the epkinly market involves securing regulatory clearances for innovative therapeutic approaches, such as bispecific antibody therapies, aimed at boosting treatment effectiveness and expanding available therapeutic options. These bispecific antibody therapies represent a type of immunotherapy where antibodies are specifically engineered to bind simultaneously to two distinct antigens or targets. As an illustration, in June 2024, AbbVie Inc., a US-based biotech company, obtained FDA approval for EPKINLY (epcoritamab-bysp), making it the first bispecific antibody for adults diagnosed with relapsed or refractory follicular lymphoma (FL) after undergoing two or more lines of systemic therapy. This novel treatment engages the immune system by dually targeting CD20 and CD3, which led to a remarkable overall response rate of 82% in clinical trials. Administered subcutaneously following a step-up dosing regimen, EPKINLY offers a new possibility for patients with limited alternative treatments. This approval marks a substantial advancement in the management of follicular lymphoma, providing optimism for improved patient outcomes.
Epkinly Market Key Players Shaping Industry Direction
Major companies operating in the epkinly market are AbbVie Inc., Genmab A/S.
View The Full Epkinly Market Report:
Epkinly Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the epkinly market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the epkinly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
